文献速递妇科

复发性低级别上皮性卵巢癌患者的生存与预后因素:NOGGO元数据库五项前瞻性II/III期试验分析

Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
PubMed 文献 · Gynecol Oncol · 2019-06-21

该探索性分析基于德国东北妇科肿瘤学会(NOGGO)数据库五项随机II/III期试验,纳入1050例首次复发上皮性卵巢癌患者,其中低级别42例(4%)、高级别1008例(96%)。在铂耐药复发中,低级别患者无进展生存期(PFS)和总生存期(OS)显著优于高级别患者;低级别复发中无铂间期无预后意义,非浆液性组织学与更差结局相关。

要点

  • 铂耐药复发中,低级别患者PFS 7.6个月 vs 高级别3.6个月(p=0.03),OS 41.9个月 vs 9.5个月(p=0.002)。
  • 铂敏感复发中,低级别与高级别患者的PFS和OS无显著差异。
  • 低级别复发中,无铂间期无预后意义;非浆液性组织学与更差PFS相关。

核心结论

  • 本研究提示,无铂间期在复发性低级别上皮性卵巢癌中无预后意义,非浆液性组织学与复发时更差结局相关。
  • 二次肿瘤细胞减灭术达无肉眼残留和腹水与疾病进展独立相关。

研究设计与样本

  • 此为NOGGO数据库内的探索性分析,纳入五项比较不同化疗方案的随机II/III期试验。
  • 共1050例首次复发上皮性卵巢癌患者,低级别42例(4%),高级别1008例(96%)。
  • 进行了生存分析和Cox比例回归模型。

主要发现

  • 铂敏感复发中,低级别与高级别患者的PFS(8.7个月 vs 9.7个月,p=0.7)和OS(23.9个月 vs 24.8个月,p=0.9)无显著差异。
  • 铂耐药复发中,低级别患者PFS(7.6个月 vs 3.6个月,p=0.03)和OS(41.9个月 vs 9.5个月,p=0.002)显著优于高级别患者。
  • 低级别上皮性卵巢癌中,铂敏感与铂耐药复发的PFS(p=0.91)和OS(p=0.25)无显著差异。
  • 低级别非浆液性组织学患者PFS低于低级别浆液性组织学患者(p=0.004)。
  • Cox回归分析显示,腹水存在和二次肿瘤细胞减灭术后残留病灶与低级别复发性上皮性卵巢癌的较差PFS独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Low-grade epithelial ovarian cancers (EOC), constitute the minority among all epithelial cancers. Our study objective was to focus on low-grade recurrent EOC and compare the survival with high-grade disease, as well as in regard to "platinum-sensitive" and "-resistant" recurrences according to platinum-free interval. METHODS: This is an exploratory analysis within the North-Eastern German Society of Gynecological Oncology (NOGGO) database including five randomized phase II/III trials comparing different chemotherapy regimens in recurrent EOC. We conducted survival analyses and cox-proportional regression models. RESULTS: Out of 1050 patients having the first recurrence, 42 (4%) patients had low-grade and 1008 (96%) patients had high-grade disease. In the subgroup of platinum-sensitive recurrences, progression-free survival (PFS) (8.7 m vs 9.7 m, p = 0.7) and overall survival (OS) (23.9 m vs 24.8 m, p = 0.9) did not differ between low-grade and high-grade diseases. In platinum-resistant recurrences, patients with low-grade ovarian cancer had significantly better PFS (7.6 m vs 3.6 m, p = 0.03) and OS (41.9 m vs 9.5 m p = 0.002) in comparison to those with high-grade cancer. At low-grade EOC, there were no significant PFS (p = 0.91) and OS (p = 0.25) differences between platinum-sensitive and -resistant recurrences. Patients with low-grade non-serous histology had lower PFS with compared to those with low-grade serous histology (p = 0.004). At cox regression analysis presence of ascites and residual disease after secondary cytoreductive surgery were independently associated with poor PFS within low-grade recurrent EOC. CONCLUSION: Our study indicates, platinum-free interval does not have any prognostic significance at recurrent low-grade EOC and non-serous histology is associated with poorer outcome in recurrence. Secondary surgical cytoreduction to no-gross residual disease and ascites are independently associated with disease progression.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Canaz E, Grabowski JP, Richter R, et al. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecol Oncol. 2019. PMID: 31230821. doi:10.1016/j.ygyno.2019.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。